THE EFFECT OF SGLT2 INHIBITOR THERAPY ON THE COURSE OF ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Keywords:
Chronic kidney disease, atrial fibrillation, SGLT2 inhibitors, heart failure, cardioprotective therapy, nephroprotection.Abstract
Chronic kidney disease (CKD) is one of the leading risk factors for the
development of cardiovascular complications, including atrial fibrillation (AF). In
patients with CKD, AF occurs significantly more frequently and is associated with an
increased risk of stroke, progression of heart failure, and mortality. In recent years,
sodium–glucose cotransporter-2 (SGLT2) inhibitors have attracted considerable
attention due to their pronounced nephroprotective and cardioprotective effects that
extend beyond their glucose-lowering properties. However, the impact of this drug
class on the course of AF in patients with CKD remains insufficiently studied.
References
1. Benjamin E.J., Wolf P.A., D’Agostino R.B., et al. Impact of atrial fibrillation
on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
doi: 10.1161/01.cir.98.10.946.
2. Zoni-Berisso M., Lercari F., Carazza T., et al. Epidemiolog of atrial
fibrillation: European perspective. Clin Epidemiol. 2014;16(6):213-220. doi:
10.2147/CLEP.S47385.
3. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА:
Эпидемиология фибрилляции предсердий в репрезентативной выборке
Европейской
части
Российской
Федерации.
Кардиология.
2022;62(4):12-19.
doi:
10.18087/cardio.2022.4.n1997.
4. Mareev Yu.V., Polyakov D.S., Vinogradova N.G., et al. Epidemiology of
atrial fibrillation in a representative sample of the European part of the Russian
Federation. Analysis of EPOCH-CHF study. Kardiologiia. 2022;62(4):12-19. doi:
10.18087/cardio.2022.4.n1997. [In Russian]
